Information om | Engelska ordet BRADYKININ

Exempel på hur man kan använda BRADYKININ i en mening

• ACE inhibitors inhibit the activity of angiotensin-converting enzyme, an important component of the renin–angiotensin system which converts angiotensin I to angiotensin II, and hydrolyses bradykinin.
• B cell - bacteria - bacterial conjugation - bacterial outer membrane protein - bacterial protein - bacteriorhodopsin - base (chemistry) - base pair - base sequence - basic fibroblast growth factor - Bcl-2 - bcr-abl fusion protein - benzene - benzene ring - beta-2 microglobulin - beta adrenergic receptor - beta sheet - beta-1 adrenergic receptor - beta-2 adrenergic receptor - beta-thromboglobulin - bioaccumulation - biochemistry - biodiversity - bioethics - biogenic amine receptor - bioinformatics - biological membrane - biologist - biology - biomechanics - biomedical model - biomolecule - biophysics - biopolymer - biosalinity - biotechnology - BLAST - blood proteins - boiling point - Boltzmann distribution - Boltzmann principle - bombesin - bombesin receptor - bone morphogenetic protein - bradykinin - bradykinin receptor - BRCA1 - buffer solution.
• High-molecular-weight kininogen (HMWK or HK) is a circulating plasma protein which participates in the initiation of blood coagulation, and in the generation of the vasodilator bradykinin via the kallikrein-kinin system.
• Together with colleagues Wilson Teixeira Beraldo and Gastão Rosenfeld, Rocha e Silva discovered in 1948 the powerful hypotensive effects of bradykinin in animal preparations.
• Sérgio Henrique Ferreira (October 4, 1934 – July 17, 2016) was a Brazilian physician and pharmacologist noted for the discovery of the bradykinin potentiating factor, which led to new and widely used anti-hypertension drugs — the ACE inhibitors.
• crabro venom contains neurotransmitters such as dopamine, serotonin, histamine and noradrenalineneurotoxin apamin, as well as enzymes phospholipase A and hyaluronidase, and proteins melittin and bradykinin.
• Deficiency of C1-inhibitor permits plasma kallikrein activation, which leads to the production of the vasoactive peptide bradykinin.
• While in São Paulo, Beraldo was part of the pharmacological research team of the Biological Institute of São Paulo, led by Maurício Rocha e Silva, which, in 1949, discovered bradykinin, a new autopharmacological principle which was released in the blood by the snake venom of the jararaca (lancehead), Bothrops jararaca.
• Chemical factors produced during inflammation (histamine, bradykinin, serotonin, leukotrienes, and prostaglandins) sensitize pain receptors, cause local vasodilation of the blood vessels, and attract phagocytes, especially neutrophils.
• For instance, bradykinin, nitric oxide / peroxynitrite, prostaglandins, vascular permeability factor (also known as vascular endothelial growth factor VEGF), tumor necrosis factor and others.
• Plasma kallikrein liberates kinins (bradykinin and kallidin) from the kininogens, peptides responsible for the regulation of blood pressure and activation of inflammation.
• It was first described in the cytosol of rabbit brain as an oligopeptidase, which degrades the nonapeptide bradykinin at the Pro-Phe bond.
• Neprilysin is a zinc-dependent metalloprotease that cleaves peptides at the amino side of hydrophobic residues and inactivates several peptide hormones including glucagon, enkephalins, substance P, neurotensin, oxytocin, and bradykinin.
• Angioedema - The ADE of angioedema found in patients using Aliskiren is due to the inhibition of bradykinin degradation which occurs within the Renin-Angiotensin System (RAAS).
• Omapatrilat angioedema was attributed to its dual mechanism of action, inhibiting both angiotensin-converting enzyme (ACE), and neprilysin (neutral endopeptidase), both of these enzymes are responsible for the metabolism of bradykinin which causes vasodilation, angioedema, and airway obstruction.
• In 1964, a study delivered chemical agents such as acetic acid, bradykinin, and kaolin to mice intraperitoneally in order to study a "squirming" response.
• Therefore, nociceptors are easily sensitised by agents such as bradykinin and nerve growth factor, which are released at the site of tissue injury, ultimately causing changes to ion channel conductance.
• Defective or missing C1-inhibitor permits activation of kallikrein, a protease that is responsible for liberating bradykinin from its precursor kininogen.
• Some substances such as bradykinin, nerve growth factor and protons have been reported to sensitize the TRPV1 receptor.
• Neuropeptides include bradykinin, cholecystokinin, corticotropin-releasing factor (CRF), galanin, MCH, MSH, Neuropeptide Y (NPY), Neurotensin, Opioids, orexin, oxytocin, somatostatin, tachykinins, TRH, CUP, and vasopressin.

Förberedelsen av sidan tog: 107,43 ms.